Not Signed In - Cancer Patients Show Reduced Pain And Lower Analgesic Consumption Following Treatment With QUADRAMET(R)
Wed, 20 Sep 2006 07:00 AM EST
... Cytogen Corporation (Nasdaq: CYTO) today announced the publication of new data relating to the Company's QUADRAMET(R) (samarium Sm-153 lexidronam injection) product. The publication, "Incident pain and analgesic consumption decrease after samarium infusion: a pilot study" appears in a recent issue of the peer-reviewed journal Supportive Care in Cancer (Support Care Cancer. 2006 Sep 12). [click link for full article] ...
Related Topics
- Back Pain
- Pain
- Abdominal Pain
- Pain - Chronic
- Chronic Pain
- Low Back Pain
- Bone Cancer
- Pain Control
- Prostate Cancer
- Smoking Cessation and Continued Risk in Cancer Patients
- Treatment
- Kidney Cancer
- Pancreatic Cancer
- Esophageal Cancer
- Stomach Cancer
- Bladder Cancer
- Uterine Cancer
- Pain, Chest
- Chest Pain
- Cancers
email this page
print this page
bookmark this page
feedback on this page
